Pip-tazo causes mortality over cefepime, researchers loudly claim

What conclusions does this widely shared paper actually support?

A retrospective observational study based on a “natural experiment” during a piperacillin-tazobactam shortage in 2015-2016 at the University of Michigan (forcing increased use of cefepime instead of pip-tazo) concluded that for every 20 patients treated with pip-tazo instead of cefepime, one dies as a result.

You might say, wait— didn’t ACORN show nomina…